1Press MF,Bernstein L,Thomas PA,et al.HER-2/neu gene amplification characterized by fluorescence in situ hybridization:poor prognosis in node-negative breast carcinomas.J Clin Oncol,1997,15:2894-2904.
2Ratclitte N,Wells W,Wheeler K,et al.The combination of in situ hybridization and immunohistochemical analysis:an evaluation of HER-2/neu expression in paraffin-embedded breast carcinomas and adjacent normal-appearing breast epithelium.Mod Pathol,1997,10:1247-1252.
4Tanner M,Gancberg D,DiLeo A,et al.Chromogenic in situ hybridization:a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples.Am J Pathol,2000,157:1467-1472.
5Zhao JX,Wu R,Au A,et al.Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma.Mod Pathol,2002,15:657-665.
6Gupta D,Middleton LP,Whitaker MJ,et al.Comparison of fluorescence and chromogenic in situ hybridization for detection of HER-2/neu oncogene in braest cancer.Am J Clin Pathol,2003,119:381-387.
二级参考文献17
1Van de Vijver MJ. Assessment of the need and appropriate method for testing for the human epidermal growth factor receptor-2 (HER2).Eur J Cancer, 2001, 37Suppl 1: 11-17.
2Ross JS, Gray GS. Targeted therapy for cancer: the HER-2/neu and Herceptin story. Clin Leadersh Manag Rev, 2003, 17:333-340.
3Vogel-C, Cobieigh MA, Tripathy D? et al. First-line, single-agent Herceptin ( R ) ( trastuzumab ) in metastatic breast cancer: a preliminary report. Eur J Cancer, 2001, 37 Suppl 1:25-29.
4Hammock L, Lewis M, Phillips C, et al. Strong Her-2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization. Hum Pathol, 2005,36 : 1043-1047.
5Ross JS, Fletcher JA, Linette GP, et al. The HER-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy.Oncologist, 2003, 8:307-325.
6Hicks DG, Tubbs RR. Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization: a technical review with interpretive guidelines. Hum Pathol, 2005, 36:250-261.
7Yarden Y. Biology of HER2 and its importance in breast cancer.Oncology, 2001, 61 Suppl 2:1-13.
8Reed W, Hannisdal E, Boehler PJ, et al. The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14-30 years.Cancer, 2000,88:804-813.
9Berry DA, Muss HB, Thor AD, et al. HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive,node-positive breast cancer. J Clin Oncol, 2000, 18:3471-3479.
10Schmidt M, Lewark B, Kohlschmidt N, et al. Long-term prognostic significance of HER-2/neu in untreated node-negative breast cancer depends on the method of testing. Breast Cancer Res,2005,7 :R256-R266.
